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Abstract
The clinical effectiveness and scar quality of the randomized controlled trial compar-
ing enzyme alginogel with silver sulfadiazine (SSD) for treatment of partial thickness
burns were previously reported. Enzyme alginogel did not lead to faster wound
healing (primary outcome) or less scar formation. In the current study, the health-
related quality of life (HRQoL), costs, and cost-effectiveness of enzyme alginogel
compared with SSD in the treatment of partial thickness burns were studied. HRQoL
was evaluated using the Burn Specific Health Scale-Brief (BSHS-B) and the EQ-5D-
5L questionnaire 1 week before discharge and at 3, 6, and 12 months postburn. Costs
were studied from a societal perspective (health care and nonhealth-care costs) for a
follow-up period of 1 year. A cost-effectiveness analysis was performed using cost-
effectiveness acceptability curves and comparing differences in societal costs and
Quality Adjusted Life Years (QALYs) at 1 year postburn. Forty-one patients were ana-
lyzed in the enzyme alginogel group and 48 patients in the SSD group. None of the
domains of BSHS-B showed a statistically significant difference between the treat-
ment groups. Also, no statistically significant difference in QALYs was found between
enzyme alginogel and SSD (difference −0.03; 95% confidence interval [CI], −0.09 to
0.03; P = .30). From both the health care and the societal perspective, the difference
Abbreviation: BSHS-B, Burn Specific Health Scale-Brief; HRQoL, Health-related quality of life; ICER, incremental cost-effectiveness ratio; SSD, silver sulfadiazine; TBSA, total body surface area;
QALYs, quality adjusted life years; VAT, Visual Analogue Thermometer.
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in costs between enzyme alginogel and SSD was not statistically significant: the dif-
ference in health-care costs was €3210 (95% CI, €-1247 to €7667; P = .47) and in
societal costs was €3377 (95% CI €-6229 to €12 982; P = .49). The nonsignificant dif-
ferences in costs and quality-adjusted life-years in favor of SSD resulted in a low
probability (<25%) that enzyme alginogel is cost-effective compared to SSD. In con-
clusion, there were no significant differences in quality of life between both treat-
ment groups. Enzyme alginogel is unlikely to be cost-effective compared with SSD in
the treatment of partial thickness burns.
1 | INTRODUCTION
The optimal treatment of partial thickness burns remains an unsolved
challenge in the absence of a gold standard treatment.1-3 The available
literature is mainly based on clinical studies of poor quality that report
mostly on clinical outcomes (eg, wound healing) and incidentally on
scar quality.1,4,5 Therefore, there is a need for well-designed trials that
not only evaluate clinical outcomes and scar formation but also
health-related quality of life (HRQoL), costs, and cost-effectiveness to
help establish optimal treatment of partial thickness burns.
Two retrospective studies showed faster wound healing when
enzyme alginogel, which is a hydrated alginates polymers in a poly-
ethyleneglycol (PEG) matrix embedded with a biologic enzyme system
of glucose oxidase, lactoperoxidase and guaiacol was compared with
SSD in the treatment of partial thickness burns, while no data were
available with regard to scar formation, HRQoL, costs, or cost-effec-
tiveness.6,7 Therefore, our research group performed a randomized
controlled trial (RCT) comparing enzyme alginogel with SSD in the
treatment of partial thickness burns (FLAM study).8 Enzyme alginogel
was not found to be superior with regard to clinical outcomes such as
wound healing time (primary outcome), pain, incidence of infection,
and scar quality, although patients in the enzyme alginogel group
required significantly less dressing changes compared with the SSD
group.9 Less dressing changes in the enzyme alginogel group were
expected to lead to less treatment costs compared with the SSD
group. In this light, HRQoL, costs, and cost-effectiveness of the treat-
ment modalities might be decisive factors for choosing between the
two treatments in clinical practice. Therefore, this study evaluated the
HRQoL, costs, and cost-effectiveness of enzyme alginogel compared
with SSD in the treatment of partial thickness burns.
2 | MATERIAL AND METHODS
2.1 | Study design
Patients with partial thickness burns participated in an open label,
multicenter RCT comparing the clinical effectiveness, quality of life,
and costs of enzyme alginogel with SSD. The detailed study protocol
was published previously.8 The study was approved by the Medical
Research Ethics Committee Noord-Holland (NL43671.094.13) and
conducted at two Dutch Burn Centers (Red Cross Hospital, Beverwijk
and Maasstad Hospital, Rotterdam) from February 2014 until
September 2015. Patients were eligible for the study if they were
18 years or older; had partial thickness burns of minimally 1% affected
total body surface area (TBSA); presented within 48 hours of the burn
injury; were mentally competent or temporary incompetent (because
of sedation and/or intubation); and provided written informed consent.
Patients were excluded if they had TBSA >30%; burns caused by
chemicals, electricity, or radiation; if local therapy had already started;
or if the treating physician expected the patients not to be compliant
with the study protocol. The patients were randomly allocated to treat-
ment with either Flaminal Forte (Flen Pharma, Belgium), which is an
enzyme alginogel consists of 5.5% hydrated alginates and a biologic
antimicrobial system (glucose oxidase, lactoperoxidase, and guaiacol)
or Flamazine (Sinclair Pharmaceuticals, Surrey, United Kingdom) which
consists of silver sulfadiazine (SSD) 10 mg/g in hydrophilic crème base.
2.2 | Time to wound healing and operation
In addition to previously published results on clinical effectiveness of
the treatment modalities in the FLAM study,9 of the results for time
to wound healing and need for operation were analyzed in subgroups
of patients with different wound depths, based on results of the Laser
Doppler imager in combination with the clinical diagnosis.10,11 From a
clinical point of view, stratification of different wound depths of par-
tial thickness wounds is important because superficial and intermedi-
ate partial thickness burns are likely to heal spontaneously in less than
3 weeks, while deep partial thickness burns often require operation.11
2.3 | Health-related quality of life
HRQoL was evaluated using the Dutch version of the Burn Specific
Health Scale-Brief (BSHS-B) and the EQ-5D-5L questionnaire 1 week
before discharge and at 3, 6, and 12 months postburn. The BSHS-B is
a valid and reliable self-administered questionnaire with 40 items that
cover nine domains: simple abilities, heat sensitivity, hand function,
treatment regimens, work, body image, affect, interpersonal relation-
ships and sexuality. All items are scored on a scale from 0 (extreme dif-
ficulty) to 4 (no difficulty at all).12,13
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The EQ-5D-5L is a generic quality of life questionnaire, which is
widely used in economic evaluations, because it enables the compari-
son of quality of life outcomes for all kinds of interventions and differ-
ent diseases. The questionnaire comprises two components.14 The
first is a descriptive system that defines health states based on five
dimensions: mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression. Each dimension is scored with one item on five
levels ranging from no problems to extreme problems. The combina-
tion of the scores for the five dimensions can be translated to utility
values, ranging from 0 (health as bad as death) to 1 (perfect health),
based on a so-called tariff, which is obtained by the valuation of the
Dutch population for the different health states.15 The second com-
ponent is a Visual Analogue Scale (VAS), on which the burn patients
rate their health state, ranging from 0 (worst imaginable health state)
to 100 (perfect health). The VAS score can also be transformed to a
utility value using the power transformation 1-(1-VAS/100)1.61.16
Quality adjusted life years (QALYs) were used to evaluate the
cost-effectiveness over a period of 12 months. QALYs combine EQ-
5D-5L and EQ-VAS utilities values with duration of the follow-up
period.17 QALYs were calculated from the area-under-the-curve
method of the utilities obtained from the EQ-5D during the
12 months of follow-up.14
2.4 | Costs
Costs were studied from the societal perspective, which included both
health-care costs in and outside the hospital and nonhealth-care costs
(productivity loss and travel costs). Data on health-care use were
recorded prospectively by the FLAM study research team as part of
the case record form during admission and by means of patient ques-
tionnaires at 3, 6, and 12 months postburn. Costs were calculated by
multiplying the volumes of health-care use by the corresponding unit
prices. Because of the 1-year time horizon, costs were not discounted.
Costs were expressed in Euros and converted to the 2018 price level
using the general Dutch consumer price index.18
2.4.1 | Treatment
Costs of treatment were determined by microcosting, taking into
account used materials and personnel time. To assess costs of wound
care, material and personnel time (ICU and non-ICU nurse) needed for
each dressing change were recorded daily for each patient. The unit
price for materials was obtained from the financial department of the
Red Cross Hospital, Beverwijk. Subsequently, total material costs
were calculated for each patient. Personnel time needed for each
dressing change was recorded in hours. Costs of personnel time per
hour were based on the gross salary of the nurses, increased with a
surcharge for holiday allowance and social charges.19 Personnel,
material, and equipment costs of surgery were obtained from a previ-
ous Dutch study by Hop et al.20 Personnel costs were multiplied by
time (surgical and anesthesia team) needed for each operation
recorded in the current study. For each patient, information on recon-
structive surgery, use of blood products, pressure clothes and silicone
therapy were recorded prospectively during hospital admission and
the follow-up period up to 12 months postburn. The unit price for the
reconstructive surgery was derived from a previous Dutch study on
this subject.21 Unit prices of blood products, pressure clothes, and sili-
cone therapy were derived from the financial department and
supplier.
2.4.2 | Diagnostics and clinical consultations
during hospitalization
Diagnostic procedures included bronchoscopy, swabs, laboratory
tests, and radiology, which were recorded daily during admission. Unit
prices of these diagnostic procedures were obtained from the Dutch
manual for costing in economic evaluation and the Dutch Healthcare
Authority.19,22
2.4.3 | Burn center stay and outpatient burn care
Length of burn center stay in days and number of outpatient burn
care visits during the follow-up period of 12 months postburn were
recorded on the case record forms. Burn center stay in days included
days spent in the Intensive care Unit (ICU) of the burn center, non-
ICU burn center days and readmittance days. Unit costs were
obtained from a previous Dutch study by Hop et al.23 Other health-
care use (rehabilitation, nursing home, visits to general practitioners,
and allied health-care professionals outside the hospital) was assessed
by questionnaires during follow-up period of 12 months. Unit costs
were obtained from the Dutch manual for costing in economic
evaluation.19
2.4.4 | Nonhealth-care costs
Nonhealth-care costs included costs of loss of economic productivity
due to absence from work (by both patients and partner) and travel
costs. Data on work absence were collected by questionnaires from
the patients at 3, 6, and 12 months postburn. Productivity losses were
valued using the friction cost method.24
3 | STATISTICAL ANALYSIS
All analyses followed the intention-to-treat principle. All statistical
analyses were conducted with IBM SPSS Statistics for Windows, ver-
sion 22 (IBM Corp., Armonk, N.Y., USA). BSHS results were presented
as median, while utility values and costs were presented as mean. Fur-
thermore, a two-sided t-test or Mann-Whitney test was used for com-
paring continuous data, and a two-sided Chi-square test or Fisher's
exact test for categorical data.
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For the cost-effectiveness analysis, multiple imputation by
chained equations was used to reduce possible bias caused by missing
data. Missing utility values or cost items were imputed using a
switching regression model that included age, gender, TBSA, location
of the study area and randomization group. Cost and QALYs were
compared using the net benefit approach.25 Depending on the willing-
ness to pay for a QALY, a strategy is cost-effective compared with an
alternative strategy if it has a higher net benefit (willingness to pay ×
QALYs - costs). Cost-effectiveness acceptability curves depict the
probability that a strategy is cost-effective as a function of willingness
to pay, given the statistical uncertainty in costs and QALYs. The
threshold of willingness to pay that is commonly accepted in the
Netherlands is between €20 000 and € 80 000 per QALY, depending
on disease burden.26 The base-case cost-utility analysis compared
QALYs at 1 year on the basis of the EQ-5D-5L (Dutch tariff). Sensitiv-
ity analyses were carried out using the EQ-VAS as a utility measure.
4 | RESULTS
4.1 | Study population
Of the 90 included patients, 89 patients were analyzed. One patient
in the enzyme alginogel group discontinued participation in the trial
during the admission period. The treatment groups were comparable
with regard to age, gender, percentage of TBSA of the study area,
trauma mechanism and anatomical location of the study area
(Table 1). Lost to follow-up were 4/41 (10%) patients in the enzyme
alginogel group and 3/48 (6%) patients in the SSD group.
4.2 | Time to wound healing and operation
As represented in Table 2, the median time to wound healing and
need for operation did not differ between the enzyme alginogel group
and the SSD group, neither within the subgroup of patients with
superficial and/or intermediate partial thickness buns nor in the sub-
group of patients with deep partial thickness burns.
4.3 | Quality of life
For all nine domains of the BSHS-B, the amount of perceived prob-
lems decreased after hospital discharge. No statistically significant or
clinically relevant differences between the treatment groups were
found in any of the nine domains of BSHS-B at any follow-up moment
(Table 3). The utility values for the patients' health states according to
the Dutch EQ-5D-5L and EQ-VAS at 3, 6, and 12 months also showed
no statically significant or clinically relevant differences between the
treatment groups (Table 4). The mean QALYs based on the EQ-5D-5L
results over the 12 months postburn were 0.81 for enzyme alginogel
group and 0.84 for SSD group. The difference in mean QALYs was
not statistically significant (−0.03; 95% confidence interval [CI] −0.09
to 0.03; P = .30). The mean QALYs obtained using the VAS over the
study period were 0.89 for enzyme alginogel group and 0.90 for SSD
group. The difference in mean QALYs of EQ-VAS was not statistically
significant (−0.01; 95% CI: −0.05 to 0.02; P = .42).
TABLE 1 Characteristics of patients
Characteristic
Enzyme
alginogel (n = 41)
Silver
sulfadiazine
(n = 48)
Age in years, mean (SD) 50 (15) 43 (16)
Male gender, n (%) 32 (78) 39 (81)
%TBSA study area, median
(range)
• Partial thickness burns 3 (1-10) 3 (1-16)
• Superficial and/ or
intermediate
2 (1-9) 2 (1-9)
• Deepa 2 (2-10) 4 (1-16)
Trauma mechanism, n (%)
• Scald 4 (10) 7 (15)
• Flame 20 (49) 21 (44)
• Flash 12 (29) 16 (33)
• Hot grease 2 (5) 4 (8)
• Steam 3 (7) 0 (0)
Location of study area, n (%)
• Head and neck 1 (2) 1 (2)
• Trunk (anterior) 10 (24) 6 (13)
• Trunk (posterior) 6 (15) 2 (4)
• Upper extremities 16 (39) 24 (50)
• Lower extremities 8 (20) 15 (31)
aBurn wounds with deep partial thickness burns as the deepest wound
depth.
TABLE 2 Time to wound healing and need for operation based on
burn wound depth of the partial thickness burns
Outcome measure
Enzyme
alginogel
(n = 41)
Silver
sulfadiazine
(n = 48) P
Superficial and/or intermediate
partial thickness burns
Time to wound healing (days),
median (range), n
15 (8-32)
n = 19
12 (7-27)
n = 22
.08a
Need for operation, n (%) 5/19 (26%) 5/22 (23%) .89b
Deep partial thickness burnsc
Time to wound healing (days),
median (range), n
19 (11-49)
n = 22
18 (11-48)
n = 26
.92a
Need for operation, n (%) 16/22 (73%) 19/26 (73%) .79b
aMann-Whitney test.
bChi-square test.
cBurn wounds with deep partial thickness burns as the deepest wound
depth.
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TABLE 3 Scores on the Burn Specific Health Scale (BSHS)-Brief during follow-up of 12 months
Enzyme alginogel silver sulfadiazine
No. Median Range No. Median Range Pa
Simple abilities
During admission 38 2.7 0.0-4.0 44 2.8 0.0-4.0 .21
3 months postburn 35 4.0 0.3-4.0 41 4.0 0.0-4.0 .43
6 months postburn 34 4.0 0.0-4.0 38 4.0 0.0-4.0 .08
12 months postburn 34 4.0 0.0-4.0 36 4.0 3.7-4.0 .08
Heat sensitivity
During admission 36 2.8 0.0-4.0 35 3.0 0.4-4.0 .32
3 months postburn 34 3.5 0.2-4.0 42 3.4 0.0-4.0 .77
6 months postburn 34 3.6 1.8-4.0 39 3.8 0.8-4.0 .14
12 months postburn 34 3.6 1.8-4.0 36 3.8 1.4-4.0 .40
Hand function
During admission 38 3.2 0.0-4.0 44 3.2 0.0-4.0 .98
3 months postburn 35 4.0 1.0-4.0 41 4.0 0.0-4.0 .99
6 months postburn 34 4.0 0.0-4.0 38 4.0 0.0-4.0 .37
12 months postburn 34 4.0 0.0-4.0 36 4.0 2.8-4.0 .17
Treatment regimens
During admission 37 3.2 0.2-4.0 33 3.2 0.0-4.0 .42
3 months postburn 34 3.8 0.2-4.0 42 4.0 0.8-4.0 .86
6 months postburn 34 4.0 2.0-4.0 39 4.0 2.2-4.0 .80
12 months postburn 34 4.0 2.0-4.0 36 4.0 0.8-4.0 .38
Work
During admission 36 2.0 0.0-4.0 40 1.1 0.0-4.0 .28
3 months postburn 35 3.3 0.0-4.0 42 3.1 0.0-4.0 .71
6 months postburn 34 3.6 0.5-4.0 39 3.8 0.0-4.0 .47
12 months postburn 34 4.0 2.3-4.0 34 4.0 0.0-4.0 .18
Body image
During admission 37 3.5 0.0-4.0 42 3.0 0.5-4.0 .34
3 months postburn 35 3.7 0.0-4.0 42 3.7 1.3-4.0 .69
6 months postburn 34 3.9 0.8-4.0 39 3.8 0.8-4.0 .61
12 months postburn 34 4.0 1.0-4.0 36 3.9 0.3-4.0 .63
Affect
During admission 37 3.4 1.0-4.0 43 3.6 1.1-4.0 .99
3 months postburn 35 3.7 1.0-4.0 42 4.0 1.4-4.0 .28
6 months postburn 34 4.0 0.7-4.0 39 4.0 2.7-4.0 .34
12 months postburn 34 4.0 2.8-4.0 36 4.0 2.4-4.0 .08
Interpersonal relationships
During admission 37 3.5 0.0-4.0 40 4.0 1.0-4.0 .09
3 months postburn 34 4.0 1.8-4.0 41 4.0 1.0-4.0 .66
6 months postburn 34 4.0 0.5-4.0 39 4.0 2.8-4.0 .56
12 months postburn 34 4.0 1.5-4.0 35 4.0 3.5-4.0 .42
Sexuality
During admission 36 4.0 0.0-4.0 38 4.0 1.3-4.0 .96
3 months postburn 35 4.0 0.0-4.0 42 4.0 0.0-4.0 .91
6 months postburn 34 4.0 0.3-4.0 39 4.0 2.0-4.0 .26
12 months postburn 34 4.0 2.3-4.0 35 4.0 2.3-4.0 .51
aMann-Whitney test.
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4.4 | Health-care costs
The mean costs of treatment per patient, including wound care,
operation and scar therapy, were €4352 for the enzyme alginogel
group and €3712 for the SSD group (Table 5). The difference in
mean costs was not statistically significant (€640; 95% CI: €-769 to
€2049; P = .37). The mean of total healthcare costs per patient,
including treatment, diagnostic procedures, clinical consultations,
burn center stay, outpatient burn care and other health-care costs
was €31 031 for the enzyme alginogel group and €27 821 for the
SSD group, which were not statistically different (difference: €3210;
95% CI: €1247 to €7667; P = .47). Burn center stay costs represen-
ted the largest part of healthcare costs (63% in the enzyme
alginogel group and 69% in the SSD group), followed by treatment
costs (14% in the enzyme alginogel group 14% and 13% in the SSD
group).
4.5 | Nonhealth-care costs and societal costs
The nonhealth-care costs consisted mainly of loss of economic pro-
ductivity due to the absence of the patient from work, next to the
absence of the partner of the patient from work and travel costs to
the burn center (Table 5). The nonhealth-care costs did not differ
significantly between the treatment groups (€10 008 for enzyme
alginogel and €9841 for SSD group, P = 0.93). Combining the total
health care and nonhealth-care costs resulted in a total mean of
societal costs per patient of €41 039 for the enzyme alginogel
group and €37 663 for the SSD group (difference: €3377; 95% CI:
€6229 to €12 982; P = .49). Burn stay costs represented the largest
part of the societal costs (48% in the enzyme alginogel group and
51% in the SSD group), followed by nonhealth-care costs (24% in
the enzyme alginogel group and 26% in the SSD group), and treat-
ment costs (11% in the enzyme alginogel group and 10% in the SSD
group).
4.6 | Cost-utility analysis
The combination of nonstatistically higher societal costs and less
favorable QALY outcomes after treatment with enzyme alginogel
compared with SSD, resulted in a low probability that enzyme
alginogel is cost effective compared to SSD. The probability that
enzyme alginogel is cost-effective compared with SSD was less than
25% for all values of the willingness to pay (Figure 1). The same
results were obtained when EQ-VAS utilities were used.
5 | DISCUSSION
The FLAM study did not show any significant differences in QALYs
and health care and societal costs between enzyme alginogel and SSD
in the treatment of partial thickness burns over a period of 1 year.
Based on the nonsignificant differences in QALYs and costs in favor
of SSD, it was concluded that enzyme alginogel is not likely to be
cost-effective compared to SSD (<25%). In both treatment groups,
most of the societal costs were caused by burn center stay, absence
from work and the treatment. Time to wound healing and need for
operation did not differ between the treatment groups, neither for
patients with superficial and/or intermediate partial thickness burns
nor for patients with deep partial thickness burns as the deepest
wound depth.
In the present study, no statistically significant or clinically rele-
vant differences were found between the treatment groups in terms
of quality of life when measured with BSHS-B. Quality of life
improved with time for all measured domains. On average, the BSHS-
B scores after burn injury were lowest for the domains “simple
abilities,” “heat sensitivity,” and “work” and improved during follow-
up, which is in line with available literature.27
In the economic evaluation, we had expected enzyme alginogel to
be cost-effective compared with SSD, because of less dressing
changes in the enzyme alginogel group. Although the patients in the
TABLE 4 Utility values after treatment with enzyme alginogel and Silver sulfadiazne. Results are expressed as mean (SE of the mean)
Measure Enzyme alginogel (n = 41) Silver sulfadiazine (n = 48) Difference Pa
EQ-5D-5L Dutch, utilities
During admission 0.57 0.53 0.04 (−0.08-0.16) .52
3 months postburn 0.80 0.84 −0.04 (−0.13-0.04) .30
6 months postburn 0.84 0.89 −0.05 (−0.12-0.02) .19
12 months postburn 0.89 0.92 −0.03 (−0.08-0.03) .30
EQ-VAS, utilities
During admission 0.75 0.78 −0.03 (−0.11-0.05) .46
3 months postburn 0.89 0.89 −0.001 (−0.05-0.05) .98
6 months postburn 0.91 0.92 −0.01 (−0.05-0.03) .56
12 months postburn 0.92 0.94 −0.02 (−0.05-0.01) .10
EQ-5D-5L Dutch, utilities: utilities obtained from EQ 5-D-5L (Dutch tariff); EQ-VAS, utilities: utilities obtained from EQ Visual Analogue Scale using the
power transformation 1-(1-VAS/100)1.61.
at test.
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TABLE 5 Mean costs of health care and nonhealth-care costs in € (2018) per patient
Enzyme alginogel (n = 41) Silver sulfadiazine (n = 48) Difference
Proportion of
patients Costs
Proportion of
patients Costs
Costs (95% confidence
interval) P
Treatment
Wound care 1.00 2481 1.00 2156 325 (−458 to 1108) .42
Surgical treatmenta 0.54 1638 0.52 1210 429 (−265 to 1123) .23
Blood products (erythrocytes) 0.07 0.94 0.08 0.61 0.34 (−1 to 2) .68
Pressure garments 0.41 211 0.52 329 −119 (−311 to 74) .23
Silicon therapy 0.20 10 0.25 10 0.04 (−10 to 10) .99
Splints 0.10 11 0.04 6 5 (−9 to 18) .51
Total treatment 1.00 4352 1.00 3712 640 (−769 to 2049) .37
Diagnostic procedures
Swabs 0.98 585 1.00 565 20 (−152 to 192) .82
Lab tests 0.66 77 0.75 92 −16 (−95 to 64) .70
Bronchoscopy 0.07 61 0.04 17 44 (−33 to 120) .27
Radiology 0.32 75 0.40 92 −17 (−105 to 71) .71
Others 0.20 12 0.21 23 −10 (−30 to 10) .31
Total diagnostic procedures 0.98 810 1.00 789 21 (−314 to 356) .90
Clinical consultations
Physiotherapist 0.78 40 0.90 45 −5 (−22 to 12) .54
Occupational therapist 0.56 22 0.56 30 −8 (−23 to 7) .31
Social worker 0.29 26 0.29 32 −7 (−34 to 22) .63
Dietitian 0.27 9 0.38 11 −2 (−10 to 6) .62
Psychologist 0.27 17 0.13 8 10 (−3 to 23) .15
Skin therapist 0.00 0.00 0.02 0.21 −0.21 (−0.61 to 0.20) .32
Psychiatrist 0.12 45 0.06 42 3 (−80 to 87) .94
Speech therapist 0.07 4 0.02 2 2 (−3 to 7) .44
Rehabilitation physician 0.02 5 0.04 3 0.55 (−8 to 9) .90
Total clinical consultations 0.90 167 0.98 174
177
−10 (−119 to 99) .85
Burn center stay
Non-ICU burn center days 1.00 15 044 1.00 14 737 307 (−3110 to 3724) .86
ICU burn center days 0.12 4271 0.29 4112 159 (−4408 to 4725) .95
Re-admittance days 0.05 348 0.04 233 114 (−418 to 647) .67
Day care 0.05 10 0.04 63 −52 (−108 to 3) .35
Total burn center stay 1.00 19 672 1.00 19 145 527 (527 to 527) 1.00
Outpatient burn care
Outpatient wound care 0.88 240 0.92 226 15 (−88 to 117) .78
Outpatient scar care 0.95 328 0.92 296 32 (−26 to 91) .28
Occupational therapy 0.27 62 0.27 70 −9 (−70 to 52) .78
Plastic surgeon 0.15 70 0.13 28 21 (−28 to 70) .40
Physiotherapist 0.27 55 0.27 62 −8 (−62 to 46) .78
Rehabilitation physician 0.05 6 0.06 19 −13 (−39 to 13) .33
Others 0.20 38 0.25 66 −28 (−103 to 47) .46
Total outpatient burn care 0.98 778 1.00 768 10 (−243 to 262) .94
Total costs specialized burn
care
1,00 28 154 1,00 26 551 1604 (−2476 to 5684) .69
(Continues)
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enzyme alginogel group did require significantly less dressing changes
compared with the SSD group (enzyme alginogel group median of
85% of the days admitted in hospital [range 52-100%] while in the
SSD group almost daily, P < .0001).9 This difference in dressing
changes did not lead to significantly lower costs in the enzyme
alginogel group for several reasons. First, wound colonization in the
enzyme alginogel group was much more common compared with the
SSD group (78% vs 33%, respectively; P < .0001), which required daily
dressing changes according to our study protocol. For this reason, we
think that the a priori assumed advantage of less dressing changes in
the enzyme alginogel group was less prominent than expected, as
reflected by similar utility scores in both treatment groups. Second,
the unit price of enzyme alginogel was higher compared with SSD,
which also resulted in comparable total costs of wound care in both
treatment groups. Finally, wound care costs in the FLAM study con-
tributed only to a small part of the societal costs (enzyme alginogel
6%, SSD 5.7%; P = .42).
In the current study, burn center stay was a major component of
the health care and nonhealth-care costs (societal costs) for both
treatment groups, which is in line with other studies on burn care
costs.20,23,28-30 Productivity loss (nonhealth-care costs) represented
the second largest part of societal costs in both treatment groups
(enzyme alginogel group 24%, SSD 26%, respectively). Two Dutch
studies found comparable results ranging between 25% and 30%.20,31
A Spanish study by Sanchez found that loss of productivity accounted
for 80% of societal costs.32 The higher estimation of costs of produc-
tivity loss by Sanchez compared with the FLAM study can partially be
explained by a more comprehensive inclusion of nonhealth-care costs
using the human capital approach. In the FLAM study, however, the
friction cost method was used, including only actual absenteeism from
work in days during a friction period, that is, the time span needed to
restore the initial production level, and costs consisted of loss of pro-
ductivity of the patient and patients' partner, while Sanchez also
included loss of productivity of other caregivers. Given the composi-
tion of societal costs, future treatment and management of burn
wounds should focus on reducing the length of burn center stay and
early return to work in order to be cost-effective, while optimal treat-
ment should be warranted. Developing a wound dressing that does
not require daily dressing changes is challenging, because burn
wounds might produce considerable amount of wound exudate that
require daily (secondary) dressing changes.
TABLE 5 (Continued)
Enzyme alginogel (n = 41) Silver sulfadiazine (n = 48) Difference
Proportion of
patients Costs
Proportion of
patients Costs
Costs (95% confidence
interval) P
Other health-care costs
Rehabilitation center 0.27 944 0.25 113 831 (−328 to 1989) .15
Nursing home 0.27 290 0.31 39 251 (0.68 to 503) .05
General practitioner 0.51 59 0.48 51 8 (−31 to 48) .68
Home (nursing) care 0.51 1102 0.44 505 597 (−180 to 1374) .14
Extramural physiotherapy 0.41 196 0.52 358 −162 (−411 to 87) .20
Others 0.54 286 0.44 205 81 (−118 to 280) .42
Total other health-care costs 0.80 2877 0.69 1271 1606 (762 to 2451) .06
Total health-care costs 1.00 31 031 1.00 27 821 3210 (−1247 to 7667) .47
Nonhealth-care costs
Work absence (hours) patient 0.59 7721 0.65 8158 −436 (−4074 to 3202) 0.81
Work absence (hours) partner 0.46 2014 0.38 1400 613.44 (−1242.65 to 2469.53) 0.52
Travel costs (km) 1.00 273 1.00 283 −10 (−170 to 149) 0.90
Total nonhealth-care costs 1.00 10 008 1.00 9841 167 (−3658 to 3991) 0.93
Total societal costs per patient 1.00 41 039 1.00 37 663 3377 (−6229 to 12 982) 0.49
aincluding reconstructive surgery.
F IGURE 1 Cost-effectiveness acceptability curves for enzyme
alginogel compared with SSD. QALY, quality-adjusted life-year
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Cost studies are important to provide insights on the distribution
of costs that, for example, can be used for cost-reduction measures.
Cost-effectiveness studies on the other hand in which the difference
in cost is divided by difference in outcomes between an intervention
and its comparator to generate incremental cost-effectiveness ratio
(ICER), provide information on the most favorable balance between
cost and health-care effects.33 A systematic review on the economic
burden of burn care demonstrated that the majority of the included
studies were cost studies and only few studies were cost-
effectiveness studies.33 The authors demonstrated that mean total
health-care costs per burn patient in high-income countries were
$88 218 (range $704 to $717 306; median $44024). Noteworthy, the
interpretation of these results should be seen in the light of the wide
variety of methodological and cost prices that were used in the
included studies. The mean total health-care costs in the current study
was lower compared with the above described systematic review,
which partially can be explained by the exclusion of %TBSA >30 in
the FLAM study. Higher TBSA is associated with higher health-care
costs.33
To date, few studies have included health-care costs in the evalu-
ation of the treatments of partial thickness burns in adult patients.
Three RCTs that evaluated different treatments included only cost
studies with included cost components that ranged from only material
costs to costs including wound treatments, hospital fee, and transpor-
tation and pain medications.34-36 Another RCT on the surgical treat-
ment of partial thickness and full-thickness burn wounds with dermal
substitutes and split skin graft in combination with topical negative
pressure performed a cost-minimization analysis to compare differ-
ence in costs. No cost-effectiveness analyses were performed
because there were no significant differences in the studied effect
(elasticity).20 This study comprehensively assessed the costs including
treatments, hospital stay, clinical consultations, other health-care
costs (eg, general practitioner) and absence from work. The authors
found no significant differences between total costs per patients for
the studied interventions. Two studies performed a cost-effectiveness
analysis in the treatment of partial thickness burns in adult patients.
Sheckter et al used a decision model to study the cost-effectiveness
of enclosed silver dressings (Aquacel Ag [ConvaTec, Skillman, NJ] and
Mepilex Ag [Molnlycke Health Care, Gothenburg, Sweden]) compared
to SSD.37 Costs were based on the quantity of the used material, daily
home assistance for dressing changes, and outpatient visits. The incre-
mental cost utility ratio, comparing the difference in costs between
both treatments and QALYs, was calculated at $40 168/QALY.
Assuming a maximum willingness to pay of $50 000/QALY, authors
concluded that enclosed silver dressing were cost-effective. The
results of this study, however, should be interpreted with caution
because costs were not based on the individual patients but rather on
the volume of used materials to treat 20% TBSA burn wound for a
period of 3 weeks, including dressing changes at home if needed.
Carayanni et al compared moist exposed burn ointment (MEBO) to
standard care consisting of povidone plus Bepanthenol cream (Bayer
Consumer Care Ltd, Basel, Switzerland).38 This study included direct
medical costs related to wound treatments and medical visits by
physicians and nurses and length of hospital stay. These costs were
compared to reduction in hospital days and time of recovery. MEBO
was found to result in nonsignificantly lower total costs than standard
care and better effectiveness. Overall, it can be concluded that there
is a wide variety between studies in regard to which costs and health-
care effects are used in the economic evaluation.
To the best of our knowledge, the FLAM study is the only study
that comprehensively studied the clinical effectiveness, quality of life,
and cost-effectiveness of two standard treatments in the treatment of
partial thickness burns for a follow-up period of 1 year. Our study had
some limitations. First, the current study was not powered to detect
relevant differences in quality of life or costs. Second, data on the
daily dressing changes were missing in less than 10% and data on
QALYs (EQ-5D-5L and EQ-VAS) were missing in 14%, 17%, and 23%
at, respectively, 3, 6, and 12 months postburn. As advocated, how-
ever, multiple imputation was used to handle these missing data.39
Third, the follow-up period of this trial was 1 year, which does not
cover the long-term effects of both treatments on quality of life and
costs. However, no significant differences were found in quality of life
and costs between the treatment groups at 12 months postburn.
Since burn scar maturation and recovery is (nearly) completed at that
point in patients with partial thickness burns, it is not expected that
there are significant differences in quality of life and costs beyond
1 year postburn.
In conclusion, no significant differences were found between
enzyme alginogel and SSD in regard to burn-specific and general
quality of life. From a societal perspective, treatment of partial thick-
ness burns with enzyme alginogel is unlikely to be cost-effective com-
pared with SSD. Finally, from an economic perspective, treatment
and management of partial thickness burns should focus on reducing
length of hospital stay and early return to work, to achieve optimal
outcome.
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